Manufacturing Lilly inflates US facility investment spending by $4.5bn PharmaphorumHaving already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante.Read full story pharminent May 6, 2026 (Last updated: May 7, 2026) Pharmaphorum Having already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA Launches One-Day Inspectional Assessments to Strengthen and Expand OversightNext: Bayer looks to uphold Eylea legacy with $2.45bn Perfuse buyout Related Stories Manufacturing pharminent June 17, 2026 Manufacturing Eisai claims UK grant to expand manufacturing site pharminent June 15, 2026 Manufacturing FDA imposes import alert on Indian plant after inspectors flag GMP failings pharminent June 12, 2026
